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SUMMARY – Thiopurine S-methyltransferase (TPMT) is an enzyme that converts thiopurine 
drugs into inactive metabolites. Over 20 variant TPMT-encoding alleles, which cause reduced en-
zymatic activity, have been discovered so far. Our aim was to investigate the frequencies of variant 
alleles, i.e. genotypes in inflammatory bowel disease (IBD) patients and healthy individuals and 
to compare these frequencies with selected world populations. The most common variant alleles 
TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C were analyzed with polymerase chain reaction-
based assays and allele-specific polymerase chain reaction-based assays in 685 participants including 
459 IBD patients and 226 healthy volunteers. Study results revealed 434/459 (94.55%) IBD patients 
and 213/226 (94.25%) healthy subjects to be homozygous for the wild-type allele (TPMT*1/*1). 
TPMT*1/*2 and TPMT *1/*3C genotypes were found in 4/459 (0.87%) and 7/459 (1.53%) IBD 
patients, respectively; in healthy volunteers they were not found. TPMT*1/*3A genotype was found 
in 14/459 (3.05%) IBD patients and 13/226 (5.75%) healthy subjects. Variant genotypes were stati-
stically significantly more common in Crohn’s disease subgroup than in ulcerative colitis subgroup. 
The prevalence of variant genotypes was 23/338 (6.80%) in Crohn’s disease subgroup as compa-
red with 2/121 (1.65%) in ulcerative colitis subgroup (χ2=4.59; p=0.032). In conclusion, the most 
frequently occurring nonfunctional TPMT allele in Croatian population is TPMT*3A. The overall 
frequency of mutant alleles in our population is statistically nonsignificantly lower when compared 
with other populations of Caucasian origin. The Crohn’s disease group had more mutant alleles than 
the ulcerative colitis group. 
Key words: Crohn’s disease – genetics; Colitis, ulcerative – genetics; Thiopurine-S-methyltransferase 
deficiency; Polymorphism, genetic
Correspondence to: Agata Ladić, MD, Division of Gastroentero-
logy and Hepatology, Zagreb University Hospital Center, Kišpa-
tićeva 12, HR-10000 Zagreb, Croatia
E-mail: agata.ladic@gmail.com
Received May 19, 2015, accepted December 23, 2015
Introduction
Thiopurine drugs (azathioprine, 6-thioguanine 
and 6-mercaptopurine) are extensively used as steroid-
sparing drugs in autoimmune disorders, hematologic 
malignancies, inflammatory bowel diseases (IBD) 
and in organ transplantation1. Although very useful, 
they have a narrow therapeutic index (the ratio be-
tween therapeutic efficacy and toxicity). 
In humans, thiopurines are metabolized via three 
competing pathways: (a) oxidation by xanthine oxi-
dase (XO) (product is an inactive metabolite 6-thiou-
ric acid); (b) phosphorybosyl transfer by hypoxanthine 
guanine phosphoribosyltransferase (HGRPT) (prod-
ucts are 6-thioguanine nucleotides); and (c) methyla-
tion by thiopurine-methyltransferase (TPMT) (prod-
uct is 6-methylmercaptopurine)2. The balance between 
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these three pathways determines the amount of final 
product and henceforth the therapeutic efficacy/toxic-
ity of thiopurine drugs.
During the last three decades, TPMT has been 
extensively studied. It is a cytosolic enzyme encoded 
by TPMT gene3-5. Up to now, more than 20 allelic 
variants of the gene have been found. The majority 
of them contain a single nucleotide polymorphism 
leading to amino acid substitution. The most frequent 
allelic variants are denoted TPMT*2, TPMT*3A, 
TPMT*3B and TPMT*3C6. Each of these variants 
codes TPMT protein that undergoes rapid proteolysis 
and results in TPMT deficiency7.
Caucasians show a trimodal gene distribution: 89% 
of subjects are homozygous for wild type gene (de-
noted TPMT*1/*1); 6%-11% of subjects are heterozy-
gous (one wild-type allele and one variant allele); and 
0.33% of subjects are homozygous for some variant 
allele8-9. This finding has clinical implications: “wild-
type” patients get full dose of the drug; “heterozygous” 
patients get reduced dose; and “variant homozygous” 
patients do not get the drug in order to avoid possible 
toxicity.
The frequency distribution of variant alleles varies 
among countries, in particular among continents. Out of 
the aforementioned variant alleles, TPMT*3C is found 
mostly in African and Asian inhabitants, TPMT*3A 
in European and Northern American inhabitants, and 
TPMT*2 in Latin American inhabitants. 
A few reports on Slavic populations have re-
vealed differences in the frequency of variant alleles 
among Slavic populations10-15. This is the first study on 
TPMT polymorphisms in a Croatian population of 
IBD patients. In addition, the study compared variant 
allele frequencies between healthy Croatian subjects 
and IBD cohort in order to determine whether there 
is an association between TPMT variants and IBD; 
and between Croatian population and selected world 
populations to determine interethnic differences.
Patients, Materials and Methods
Study population
A total of 685 Croatian subjects participated in the 
study, including 459 IBD patients (338 with Crohn’s 
disease, (CD) group and 121 with ulcerative colitis, 
(UC) group) and 226 healthy adult volunteers (con-
trol group). The participants with IBD were recruited 
among in- and outpatients admitted to the Zagreb 
University Hospital Center and Osijek University 
Hospital Center. Control subjects were selected among 
hospital staff and other Zagreb citizens appointed for 
routine check-up. 
Ethical approval for the study was obtained from 
the Ethics Committees of the Zagreb University 
Hospital Center and School of Medicine, University 
of Zagreb. All procedures were performed in accor-
dance with ethical standards of the responsible com-
mittee on human experimentation (institutional and 
national) and with the Helsinki Declaration from 
1975, as revised in 2008. A written informed consent 
was obtained from all subjects.
Blood samples were collected in Vacutainer tubes 
using EDTA as anticoagulant.
TPMT genotyping
Genomic DNA was extracted from periph-
eral lymphocytes using the salting out procedure16. 
Detection of the single nucleotide polymorphisms 
(SNPs) of TPMT was carried out using a validat-
ed Real-time PCR method, TaqMan® Drug Me-
tabolism Genotyping Assay obtained from Applied 
Biosystems (Foster City, CA, USA); Assay ID: 
TPMT*2 (rs1800462), C_12091552_30; TPMT*3B 
(rs1800460), C_30634116_20; TPMT*3C  (rs1142345), 
C_19567_20. The TaqMan® primer/probe set de-
signed for each SNP allele was included in the kits.
Polymerase chain reactions (PCR) were performed 
in a 96-well microplate format in 15 µL reaction mix-
ture containing TaqMan® universal PCR master mix 
and using amplification protocol of 50 °C for 2 min, 
95 °C for 10 min, followed by 40 cycles of 92 °C for 
15 s, then 60 °C for 1.5 min. The following allelic 
discrimination analysis was carried out using the 500 
Real Time PCR Systems (Applied Biosystems, Foster 
City, CA, USA). TPMT genotyping analysis is in-
cluded in external quality control schemes (DGKL, 
Germany). 
The inflammatory bowel disease was defined ac-
cording to the standard criteria17,18.
Statistical analysis
Differences in TPMT genotype frequencies be-
tween the groups were analyzed using the χ2-test. In 
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cases of small expected frequencies (i.e. smaller than 
five), Fisher exact test was used. The frequency of each 
genotype was given with 95% confidence interval (CI). 
The level of significance of p=0.05 was considered sta-
tistically significant. The SPSS version 17 was used 
on data analysis. Test of departure of Hardy-Wein-
berg equilibrium was performed using Markov-chain 
method19, implemented in Arlequin version 3.5.1.220.
Results
A total of 685 Croatian participants were enrolled 
in the study, 459/685 (67.0%) of them IBD patients 
and 226/685 (33.0%) healthy volunteers. In IBD 
group, there were 338 patients with Crohn’s disease 
and 121 patients with ulcerative colitis.
No significant deviations from the expected Har-
dy-Weinberg proportions were observed in either 
control group (p>0.999) or IBD group (p>0.999).
None of the participants was homozygous for any 
of the investigated variant allele.
In IBD group, 434/459 (94.55%) subjects were 
homozygous for the wild-type allele (TPMT*1/*1) 
versus 213/226 (94.25%) control subjects. Difference 
in the prevalence of homozygous wild-type alleles 
between the control and IBD groups was not statisti-
cally significant (χ2=0.03; p=0.870). 
TPMT*1/*2 genotype was found in 4/459 (0.87%) 
and TPMT*1/*3C in 7/459 (1.53%) IBD patients. 
Neither of these variants was found in control group. 
Differences for these two genotypes were not statisti-
cally significant (p=0.308 and p=0.102, respectively) 
(Table 1).
TPMT*1/*3A genotype was found in 14/459 
(3.05%) IBD patients and 13/226 (5.75%) control sub-
jects. Difference between IBD and control groups did 
not reach statistical significance (p=0.087).
Analysis of CD and UC subgroups yielded statis-
tically significant differences; mutant genotypes were 
more common in CD subgroup (23/338, 6.80%) as 
compared with UC subgroup (2/121, 1.65%) (χ2=4.59; 
p=0.032) (Table 2).
Table 1. TPMT genotype frequency in IBD patients and control group
IBD Control group p-value*
n % (95% CI)# n % (95% CI)
TPMT *1/*1 434 94.55 (92.48-96.63) 213 94.25 (91.21-97.28) 0.870
Mutant type
 TPMT *1/*2 4 0.87 (0.02-1.72) 0 0.0 - 0.308
 TPMT *1/*3A 14 3.05 (1.48-4.62) 13 5.75 (2.72-8.79) 0.087
 TPMT *1/*3C 7 1.53 (0.40-2.65) 0 0.0 - 0.102
 Total 25 5.45 (3.37-7.52) 13 5.75 (2.72-8.79) 0.870
*significance level p<0.05; #95% CI = 95% confidence interval; TPMT = thiopurine-S-methyltransferase; IBD = inflammatory bowel 
diseases
Table 2. TPMT genotype frequency in Crohn’s disease and ulcerative colitis patients
Crohn’s disease Ulcerative colitis p-value*
n % (95% CI)# n % (95% CI)
TPMT *1/*1 315 93.20 (90.51-95.88) 119 98.35 (96.08-100.0) 0.032
Mutant type
 TPMT *1/*2 4 1.18 (0.03-2.34) 0 0.0 - 0.577
 TPMT *1/*3A 12 3.55 (1.58-5.52) 2 1.65 (0.0-3.92) 0.373
 TPMT *1/*3C 7 2.07 (0.55-3.59) 0 0.0 - 0.198
 Total 23 6.80 (4.12-9.49) 2 1.65 (0.0-3.92) 0.032
*significance level p<0.05; # 95% CI= 95% confidence interval; TPMT = thiopurine-S-methyltransferase 
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Croatia 1370 2.77 97.23 0.29 1.97 0.51 Realtime PCR This study
Poland 716 3.21 96.79 (0.572) 0.4 (0.697) 2.7 (0.313) 0.14 (0.277) PCR-RFLP 
a
AS-PCRb 15
Slovenia 388 4.9 95.1 (0.037) 0.0 (0.582) 4.1 (0.015) 0.5 (>0.999)
PCR-RFLP
Realtime PCR for 
TPMT*2
12
Italy 206 5.34 94.66 (0.048) 0.49 (0.504) 3.88 (0.121) 0.97 (0.333) PCR-RFLPAS-PCR 21
Serbia 400 4.0 96.0 (0.210) 0.2 (>0.999) 3.2 (0.130) 0.0 (0.361) PRC-RFLP 14
France 936 4.2 95.8 (0.067) 0.7 (0.134) 3.0 (0.115) 0.4 (>0.999) PCR-reverse dot blot 22
Sweden 1600 4.38 95.63 (0.020) 0.06 (0.188) 3.75 (0.004) 0.44 (0.771) Pyrosequencing 23
United 
Kingdom 398 5.03 94.72 (0.014) 0.5 (0.622) 4.52 (0.004) 0.25 (0.692) PCR-RFLP 24
Germany 2428 5.0 95.0 (0.001) 0.2 (0.731) 4.4 (<0.001) 0.4 (0.660) PCR Sequencing 25
China 450 1.33 98.67 (0.084) 0 (0.578) 0 (0.003) 1.33 (0.100) PCR-RFLPAS-PCR 26
Japan 384 0.8 99.2 (0.022) 0 (0.582) 0 (0.006) 0.8 (0.464) PCR-RFLPAS-PCR 27
USA 
(Caucasians) 564 3.7 96.3(0.270) 0.2 (>0.999) 3.2 (0.106) 0.2 (0.450) PCR-RFLP 28
USA (Afro-
Americans) 496 4.6 95.4 (0.046) 0.4 (0.660) 0.8 (0.082) 2.4 (<0.001)
PCR-RFLP AS-PCR 29
Colombia 280 3.93 96.07 (0.300) 0.36 (>0.999) 3.57 (0.099) 0 (0.610) PCR-RFLPAS-PCR 30
Brazil 408 4.9 95.1 (0.034) 2.2 (<0.001) 1.5 (0.511) 1.0 (0.288) PCR-RFLPAS-PCR 31
Argentina 294 4.1 95.9 (0.233) 0.7 (0.287) 3.1 (0.244) 0 (0.614) PCR-RFLPAS-PCR 32
Turkey 296 4.39 95.61 2.03 1.01 1.35 PCR-RFLP 33
Egypt 400 1.5 98.5 (0.150) 0.0 (0.580) 0.3 (0.015) 1.3 (0.157)
AS-PCR for TPMT*2
AS-Realtime PCR for *3C
PCR RFLP for *3A
34
Ghana 434 7.6 92.4 (<0.001) 0 (0.578) 0.0 (0.003) 7.6 (<0.001) PCR-RFLP 24
*significance level p<0.05; p = significance of difference in the distribution of polymorphic alleles compared to Croatians; TPMT = 
thiopurine-S-methyltransferase; a PCR-RFLP = polymerase chain reaction-restriction fragment length polymorphism; bAS-PCR = allele 
specific PCR
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Comparison of TPMT allelic frequency between 
Croatia and other countries
We were interested in the historical background 
of TPMT variants in different parts of the world and 
therefore compared our results with selected countries 
for which data were available (Table 3). 
TPMT*3A was the most prevalent variant allele 
in Croatia (27/1370, 1.97%), although with a signifi-
cantly lower frequency when compared with Slovenia 
16/388 (4.1%) (χ2=5.38; p=0.015); Germany 197/2306 
(4.4%) (χ2=11.0; p=0.001); Sweden 60/1600 (3.75%) 
(χ2=5.40; p=0.020); and United Kingdom 17/398 
(4.27%) (χ2=8.10; p=0.010)
TPMT*3C allele was found in 7/1370 (0.51%) 
of total Croatian alleles. It was significantly lower 
when compared with Ghana 33/434 (7.6%) (χ2=76.47; 
p<0.001) and Afro-American population 12/496 
(2.4%) (χ2=13.16; p<0.001).
TPMT*2 allele was found in 4/1370 (0.29%) of 
Croatian alleles. It also showed a significantly lower 
prevalence when compared with Brazil 9/408 (2.2%) 
(p<0.001) and Turkey 6/296 (2.0%) (p=0.003).
Discussion
Our results showed the most common variant al-
lele in Croatian population to be TPMT*3A (1.97% 
of mutant alleles). This is in concordance with the 
previous result reported on Croatian population35, 
although with a smaller frequency. Some differences 
in the prevalence of TPMT alleles between Cro-
ats and neighboring countries (Slovenia), as well as 
other Caucasian populations could be discussed and 
explained considering genotyping methods that were 
applied. In earlier researches, PCR-RFLP methods 
were used, which were found to be less accurate than 
Real-time PCR methods that were applied in this and 
some other recently published investigations. The re-
sults for the Croatian and Slovenian samples do not 
differ for TPMT*2 variant allele, as the Real-time 
PCR was applied on both sides, but differ for other 
alleles where the methods were different12. Our data 
are in accordance with the data obtained for Serbian 
population14. Since our laboratory is taking part in the 
external quality control schemes (DGKL, Germany) 
for TPMT genotyping, we are rather confident for the 
data presented in this study. Another advantage of our 
study was a larger number of participants compared to 
other published data.
Another interesting and to us unexpected find-
ing was that CD patients had a greater proportion 
of mutant alleles than UC patients. The frequency 
of variant alleles in the UC group was 1.65%, while 
in the CD group it was 6.80%. A limitation of this 
finding is that we had almost twice more partici-
pants in CD group than in UC group. We carried 
out this study in a tertiary referral center, where we 
had more patients with extensive Crohn’s disease. 
This possibly presents a chance finding because of a 
selection bias. A similar Russian study found a sta-
tistically significant difference in the frequencies of 
carriers of variant alleles between the malignancy 
group and control group, with a greater frequency 
in the malignancy group10. Both these findings urge 
the question that mutant alleles somehow ‘weaken’ 
the genetic construction of a person, which could be 
a basis for new investigations. 
Studies done so far speculated that TPMT*3C is 
the ancestral allele, originating from the northeastern 
Africa. This allele is present to some degree in all popu-
lations, but mostly in African and Asian. TPMT*3A 
and all other variant alleles were probably acquired over 
centuries through migrations and mixing of civiliza-
tions. Genetic analysis of modern Croatian population 
shows it to be a territory of an extraordinary genetic 
mixture36. However, there was no significant mixing 
of Croatians with African populations, which could be 
the reason why Croats exhibit mostly TPMT*3A as the 
most prevalent variant allele and not TPMT*3C, just 
as other Caucasian populations.
Conclusion
Our results confirm that TPMT*3A is the most 
prevalent allele in IBD population, as well as in gen-
eral Croatian population. This is in concordance with 
other Caucasian populations. Variant alleles were 
more prevalent in CD than in UC patients, which 
could be the basis for new investigations.
Acknowledgments
This work was supported in part by a project grant 
from the Ministry of Science, Education and Sports 
(grant No: 108-1081874-1917).
Acta Clin Croat,  Vol. 55,   No. 1,  2016 21
Agata Ladić et al. TPMT polymorphisms in an IBD patient cohort
References
  1. Paterson ARP, Tidd DM. 6-Thiopurines. In: Sartorelli AC, 
Johns DG, editors. Antineoplastic and Immunosuppressive 
Agents II. New York, Springer Verlag; 1975. p. 384-403.
  2. Remy CN. Metabolism of thiopyrimidines and thiopu-
rines: S-methylation with S-adenosylmethionine transm-
ethylase and catabolism in mammalian tissues. J Biol Chem. 
1963;238:1078-84.
  3. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum 
RM. Human thiopurine methyltransferase pharmacogenetics 
kindred with a terminal exon splice junction mutation that re-
sults in loss of activity. J Clin Invest. 1998 March;101(5):1036-
44, http://dx.doi.org/10.1172/jci1004 
  4. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen 
T, Schuetz JD, et al. Genetic polymorphism of thiopurine 
methyltransferase: clinical importance and molecular mecha-
nisms. Pharmacogenetics. 1996;6:279-90, http://dx.doi.
org/10.1097/00008571-199608000-00001 
  5. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine 
pharmacogenetics and metabolite monitoring in inflammato-
ry bowel disease. J Gastroenterol Hepatol. 2005;20:1149-57, 
http://dx.doi.org/10.1111/j.1440-1746.2005.03832.x 
  6. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacoge-
netics: monogenic inheritance of erythrocyte thiopurine meth-
yltransferase activity. Am J Hum Genet. 1980;32:651-62.
  7. Zhou S. Clinical pharmacogenomics of thiopurine S-meth-
yltransferase. Curr Clin Pharmacol. 2006 Jan;1(1):119-28, 
http://dx.doi.org/10.2174/157488406784111627 
  8. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, 
Janco R, et al. Preponderance of thiopurine S-methyltrans-
ferase deficiency and heterozygosity among patients intoler-
ant to mercaptopurine or azathioprine. J Clin Oncol. 2001 
Apr 15;19(8):2293-301.
  9. Tai HL, Fessing MY, Bonten EJ, Yanishevsky Y, d’Azzo 
A, Krynetski EY, et al. Enhanced proteasomal degradation 
of mutant human thiopurine S-methyltransferase (TPMT) 
in mammalian cells: mechanism for TPMT protein defi-
ciency inherited by TPMT*2, TPMT*3A, TPMT*3B or 
TPMT*3C. Pharmacogenetics. 1999;9:641-50, http://dx.doi.
org/10.1097/01213011-199910000-00011 
10. Samochatova EV, Chupova NV, Rudneva A, Makarova O, 
Nasedkina TV, Fedorova OE, et al. TPMT genetic varia-
tions in populations of the Russian Federation. Pediatr Blood 
Cancer. 2009 Feb;52(2):203-8, http://dx.doi.org/10.1002/
pbc.21837 
11. Slanar O, Bortlík M, Buzková H, Donoval R, Pechandová 
K, Sebesta I, et al. Polymorphisms of the TPMT gene in the 
Czech healthy population and patients with inflammatory 
bowel disease. Nucleos Nucleot Nucl. 2008 Jun;27(6):835-8, 
http://dx.doi.org/10.1080/15257770802146478 
12. Milek M, Murn J, Jaksic Z, Lukac Bajalo J, Jazbec J, Mli-
naric Rascan I. Thiopurine S-methyltransferase pharmaco-
genetics: genotype to phenotype correlation in the Slovenian 
population. Pharmacology 2006;77(3):105-14, http://dx.doi.
org/10.1159/000093278 
13. Indjova D, Atanasova S, Shipkova M, Armstrong VW, 
Oellerich M, Svinarov D. Phenotypic and genotypic analysis 
of thiopurine S-methyltransferase polymorphism in the Bul-
garian population. Ther Drug Monit. 2003 Oct;25(5):631-6, 
http://dx.doi.org/10.1097/00007691-200310000-00013 
14. Dokmanovic L, Urosevic J, Janic D, Jovanovic N, Petrucev B, 
Tosic N, et al. Analysis of thiopurine S-methyltransferase poly-
morphism in the population of Serbia and Montenegro and 
mercaptopurine therapy tolerance in childhood acute lympho-
blastic leukemia. Ther Drug Monit. 2006 Dec;28(6):800-6, 
http://dx.doi.org/10.1097/01.ftd.0000249947.17676.92 
15. Kurzawski M, Gawronska-Szklarz B, Drozdzik M. Frequen-
cy distribution of thiopurine S-methyltransferase alleles in a 
Polish population. Ther Drug Monit. 2004 Oct;26(5):541-5, 
http://dx.doi.org/10.1097/00007691-200410000-00013 
16. Miller SA, Dykes DD, Polesky HF. A simple salting out 
procedure for extracting DNA from human nucleated cell. 
Nucl Acid Res. 1988;16:1215, http://dx.doi.org/10.1093/
nar/16.3.1215 
17. Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanau-
er S, Irvine E, et al. A simple classification of Crohn’s dis-
ease: report of the Working Party for the World Congresses 
of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 
2000;6(1):8-15, http://dx.doi.org/10.1002/ibd.3780060103 
18. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Mon-
treal classification of inflammatory bowel disease: controver-
sies, consensus, and implications. Gut. 2006 Jun;55(6):749-
53, http://dx.doi.org/10.1136/gut.2005.082909 
19. Guo SW, Thompson EA. Performing the exact test of Hardy-
Weinberg proportion for multiple alleles. Biometrics. 1992 
Jun;48(2):361-72, http://dx.doi.org/10.2307/2532296 
20. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new se-
ries of programs to perform population genetics analyses un-
der Linux and Windows. Mol Ecol Resour. 2010;10:564-7, 
http://dx.doi.org/10.1111/j.1755-0998.2010.02847.x 
21. Rossi AM, Bianchi M, Guarnieri C, Barale R, Pacifici GM. 
Genotype-phenotype correlation for thiopurine-methyl-
transferase in healthy Italian subjects. Eur J Clin Pharmacol. 
2001;57:51-4, http://dx.doi.org/10.1007/s002280000246 
22. Ganiere-Monteil C, Medard Y, Lejus C, Bruneau B, Pineau 
A, Fenneteau O, et al. Phenotype and genotype for thiopurine 
methyltransferase activity in the French Caucasian popula-
tion: impact of age. Eur J Clin Pharmacol. 2004;60:89-96, 
http://dx.doi.org/10.1007/s00228-004-0732-5 
23. Haglund S, Lindquist M, Almer S, Peterson C, Taipalen-
suu J. Pyrosequencing of TPMT alleles in a general Swedish 
population and in patients with inflammatory bowel disease. 
Clin Chem. 2004;50:288-95, http://dx.doi.org/10.1373/
clinchem.2003.023846 
22 Acta Clin Croat,  Vol. 55,   No. 1,  2016
Agata Ladić et al. TPMT polymorphisms in an IBD patient cohort
24. Ameway MM, Collie-Duguid ES, Powrie RH, Adjei-
Ofori D, McLeod HL. Thiopurine methyltransferase al-
leles in British and Ghanaian populations. Hum Mol Genet. 
1999;8(2):367-70, http://dx.doi.org/10.1093/hmg/8.2.367 
25. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike 
K, Eichelbaum M, et al. Comprehensive analysis of thiopu-
rine S-methyltransferase phenotype-genotype correlation in 
a large population of German-Caucasians and identification 
of novel TPMT variants. Pharmacogenetics. 2004;14:407-
17,  http://dx.doi.org/10.1097/01.fpc.0000114745.08559.db 
26. Zhang IP, Guan YY, Wu IH, Jiang WQ , Huang M. Ge-
netic polymorphism of the thiopurine S-methyltransferase of 
healthy Han Chinese. Az’ Zheng. (Chinese Journal of Can-
cer) 2003;22:385-8. 
27. Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M. 
Genetic analysis of thiopurine methyltransferase polymor-
phism in a Japanese population. Mutat Res. 2000;448:91-5, 
http://dx.doi.org/10.1016/s0027-5107(00)00004-x 
28. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai 
HL, Pui CH, et al. Molecular diagnosis of thiopurine S-
methyltransferase deficiency: genetic basis for azathioprine 
and mercaptopurine intolerance. Ann Intern Med. 1997 Apr 
15;126(8):608-14, http://dx.doi.org/10.7326/0003-4819-
126-8-199704150-00003 
29. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski 
EY, Evans WE. Polymorphism of the thiopurine S-meth-
yltransferase gene in African-Americans. Hum Mol Genet. 
1999;8:371-6, http://dx.doi.org/10.1093/hmg/8.2.371 
30. Isaza C, Henao J, Lopez AM, Cacabelos R. Allelic variants 
of the thiopurine methyltransferase (TPMT) gene in the 
Sažetak
EPIDEMIOLOŠKA STUDIJA VARIJANTI TIOPURIN-METILTRANSFERAZE U SKUPINI HRVATSKIH 
BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA
A. Ladić, N. Božina, V. Borzan, M. Brinar, B. Vucelić i S. Čuković-Čavka
Tiopurin S-metiltransferaza (TPMT) je enzim koji sudjeluje u konverziji tiopurinskih lijekova u inaktivne metaboli-
te. Dosad je otkriveno više od 20 varijanti TPMT-kodirajućih alela. Ovi aleli uzrokoju smanjenu enzimatsku aktivnost. 
Naš cilj je bio istražiti frekvenciju varijantnih alela odnosno genotipova u bolesnika oboljelih od upalnih bolesti crijeva 
i u zdravih osoba te usporediti dobivene frekvencije s frekvencijama odabranih svjetskih populacija. Najčešći varijantni 
aleli TPMT*2, TPMT*3A, TPMT*3B i TPMT*3C analizirani su metodama lančane reakcije polimeraze, odnosno alel-
specifičnim metodama lančane reakcije polimeraze. U istraživanje je bilo uključeno 685 ispitanika; 459 ispitanika bili su 
bolesnici s upalnom bolesti crijeva, a 226 bili su zdravi dobrovoljci. Rezultati su pokazali da su 434/459 (94,55%) pacije-
nata s upalnom bolesti crijeva i 213/226 (94,25%) zdravih osoba homozigoti za divlji tip alela (TPMT*1/*1). Genotipovi 
TPMT*1/*2 i TPMT*1/*3C nađeni su u 4/459 (0,87%) odnosno 7/459 (1,53%) bolesnika; u zdravih dobrovoljaca nisu 
nađeni. Genotip TPMT*1/*3A nađen je u 14/459 (3,05%) bolesnika i 13/226 (5,75%) zdravih dobrovoljaca. Varijantni 
genotipovi bili su statistički značajno češći u podskupini bolesnika s Crohnovom bolešću, s učestalošću od 23/338 (6,80%) 
u odnosu na podskupinu bolesnika s ulceroznim kolitisom, gdje je učestalost varijantnih genotipova bila 2/121 (1,65%) 
(χ2=4,46; p=0,035). U zaključku, najčešći nefunkcionalni TPMT alel u Hrvatskoj populaciji je TPMT*3A. Ukupna fre-
kvencija varijantnih alela u našoj je populaciji statistički neznačajno niža u odnosu na druge populacije bjelačkog podrijetla. 
Bolesnici s Crohnovom bolešću imaju više varijantnih alela u odnosu na podskupinu bolesnika s ulceroznim kolitisom. 
Ključne riječi: Crohnova bolest – genetika; Kolitis, ulcerozni – genetika; Tiopurin-S-metiltransferaza, deficijencija; Polimor-
fizam, genetski 
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